Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
Miguel García-Pardo(Hospital Universitario Ramón y Cajal), Natasha B. Leighl(Princess Margaret Cancer Centre), Deirdre Kelly(University Health Network), Janice J.N. Li(University Health Network), Maisam Makarem(University Health Network)
Cited by 112
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
|Journal of Clinical Oncology|2009|1.5k
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
|Journal of Thoracic Oncology|2021|642
An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access
|American Society of Clinical Oncology Educational Book|2021|167